Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.480
+0.380 (9.27%)
At close: Nov 20, 2024, 4:00 PM
4.530
+0.050 (1.12%)
Pre-market: Nov 21, 2024, 5:08 AM EST
Cingulate Employees
Cingulate had 13 employees as of December 31, 2023. The number of employees decreased by 2 or -13.33% compared to the previous year.
Employees
13
Change (1Y)
-2
Growth (1Y)
-13.33%
Revenue / Employee
n/a
Profits / Employee
-$1,257,573
Market Cap
14.39M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13 | -2 | -13.33% |
Dec 31, 2022 | 15 | -1 | -6.25% |
Dec 31, 2021 | 16 | 4 | 33.33% |
Dec 31, 2020 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Vivos Therapeutics | 123 |
Psychemedics | 116 |
Cumberland Pharmaceuticals | 91 |
Microbot Medical | 22 |
Traws Pharma | 18 |
Minerva Neurosciences | 9 |
Autonomix Medical | 8 |
Can-Fite BioPharma | 8 |
CING News
- 13 days ago - Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - GlobeNewsWire
- 6 weeks ago - Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewsWire
- 2 months ago - Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 - GlobeNewsWire
- 3 months ago - Cingulate to Participate in Benzinga All Live Access Event - GlobeNewsWire
- 3 months ago - Cingulate Announces Adjournment of Special Meeting - GlobeNewsWire
- 3 months ago - Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy? - Invezz
- 3 months ago - Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD - GlobeNewsWire
- 3 months ago - Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved - GlobeNewsWire